

Electronic Acknowledgement Receipt

EFS ID:	3528687
Application Number:	10506998
International Application Number:	
Confirmation Number:	8833
Title of Invention:	NEW INHIBITORS OF HISTONE DEACETYLASE
First Named Inventor/Applicant Name:	Patrick Rene Angibaud
Correspondence Address:	Phillip S. Johnson Johnson & Johnson One Johnson & Johnson Plaza - New Brunswick NJ 08933-7003 US - -
Filer:	Alana G. Kriegsman/Kristin Miele
Filer Authorized By:	Alana G. Kriegsman
Attorney Docket Number:	PRD 2024-PCT
Receipt Date:	27-JUN-2008
Filing Date:	08-SEP-2004
Time Stamp:	09:06:03
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$810

RAM confirmation Number	5249				
Deposit Account	100750				
Authorized User					

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. 1.492 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes) /Message Digest	Multi Part /.zip	Pages (if appl.)
1	Request for Continued Examination (RCE)	PRD2024USPCT_RCE_06_27_08.pdf	537196 e6d51191c32eeff8277c92e3265076844e6772afdc	no	1
Warnings:					
This is not a USPTO supplied RCE SB30 form.					
Information:					
2	Information Disclosure Statement Letter	PRD2024USPCT_SupplIDS_06_27_08.pdf	231011 307d167d5519a4f5a2d5c03b35e941967221713d0	no	2
Warnings:					
Information:					
3	Information Disclosure Statement (IDS) Filed	PRD2024USPCT_SupplIDS1449_06_27_08.pdf	352900 c73d8e1bf501072c7d621c47d40c8b389717173dcf	no	1
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
4	Foreign Reference	WO00052001.pdf	21580297 e1841bf949705423a05a5311978e05482993ec	no	123
Warnings:					
Information:					
5	Fee Worksheet (PTO-06)	fee-info.pdf	8200 62f8bcb0e0a099e663ab38954125432e1532d8a7	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			22709604		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.